Preview Mode Links will not work in preview mode
Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show offers a glimpse into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the evolving dynamics in the medical and healthcare landscape. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations often focus on how technology is empowering providers, care facilities, pharmaceutical companies, and payers to improve patient outcomes and reduce friction across the healthcare landscape.  Popular Topics Include: Virtual and digital health Use of AI, ML, and robots for clinical and administrative purposes  Value-based healthcare  Precision and stratified medicine Next-generation immuno, cell, and gene therapies Vaccines for infectious diseases and oncology Biomarkers and diagnostics Rare diseases MedTech and medical devices Clinical trials  Population health Chronic conditions l Clinician and staff burnout Smart hospitals The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.

Jul 31, 2023

James Graham is the CEO of Recce Pharmaceuticals, a biotechnology company focused on the global antibiotic-resistant patient population. This new class of synthetic antibiotics takes a broad-spectrum approach to kill bacterial infections, which continue to mutate, rendering existing antibiotics ineffective.  The founding inventor of Recce is Dr. Graham Melrose, the grandfather of James, who has grown this idea into one of the top-performing biotech stocks in Australia.

James explains, "As you may know, by my accent, I’m an Australian. I think Australia found the first penicillin, which worked well for everyone around the world for a number of years. But it’s time for a new penicillin, penicillin 2.0, or one entirely synthetic, not reliant on existing natural processes. And that’s what we’ve fundamentally started with, beginning with the end in mind that is Recce antibiotics. So I really say the challenge, the silent pandemic is right upon us. You only have to look at the AMR resistance rates. I think raising at about 10% each year, certainly in certain antibiotic or indication groups. If we don’t do something, we’re just going to have these useless drugs that no one will pay the price for anyway. The business model will be broken, and everybody will be out of options. It’s really the pandemic before us."

"I hinted that R327 is synthetic. It’s entirely synthetic when all existing antibiotics to date are naturally derived. So the way antibiotics and bacteria have always worked is that you find something in nature by way of the antibiotic. The bacteria are too smart. They evolve too quickly, and let’s begin with the end in mind and create something that will work against all types of bacteria, gram-positive gram-negative in their hypercellular mutated forms, and keep on working with repeated use."

"And in the case of my origins with Recce, the inventor, Dr. Graham Melrose, is actually my grandfather. He turned 90 years old about a little over a month ago, and he's the guy who was the head of Johnson & Johnson Australasia for about a decade. He is the foundational inventor of this compound. And he and I started this company. He's the inventor. I just gave him a bit of money, and off we went. That's the easy part. He started identifying the ideal compound in his garage in Perth in Western Australia. If anyone knows where that is, it's actually the most isolated city in the world."

 @ReccePharma #AntimicrobialResistance #AMR #SuperBugs #Sepsis #UTIs #Urosepsis #SyntheticAntiInfective #Antibiotics #AustraliaBioTech

recce.com.au 

Download the transcript here 

Recce Pharmaceuticals